Experimental drug combo targets Hard-to-Treat GI cancers
NCT ID NCT04535401
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This trial tests a new drug called BAY 1895344 (elimusertib) combined with standard chemotherapy (FOLFIRI) in people with advanced or metastatic stomach or colorectal cancer. The goal is to find the safest dose and see if the combination can shrink tumors. Participants receive the drugs by mouth or IV, along with biopsies and imaging. The study is small and early-stage, focusing on safety and dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BAY 1895344 (elimusertib) plus FOLFIRI chemotherapy (irinotecan, fluorouracil, leucovorin)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced stomach or colorectal cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial with only 10 participants, so the combination may prove too toxic or ineffective. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Siteman Cancer Center at Christian Hospital
St Louis, Missouri, 63136, United States
-
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, 63376, United States
-
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141, United States
-
Siteman Cancer Center-South County
St Louis, Missouri, 63129, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Triple chemo cocktail aims to clear deadly bowel blockages in advanced stomach cancer
- New drug duo takes aim at hard-to-treat stomach cancer with liver metastases
- Wheat germ supplement studied for immune boost in advanced cancer
- New stomach cancer surgery technique shows promise in early trial
- Home monitoring may keep cancer patients out of the ER
- Tailored immunotherapy cocktail shows promise for tough stomach cancer